Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Merck
Argus Health
Accenture
Johnson and Johnson
Cantor Fitzgerald

Generated: May 26, 2019

DrugPatentWatch Database Preview

Litigation Details for JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

« Back to Dashboard

JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

Docket ➤ Sign Up Date Filed 2010-11-15
Court District Court, D. New Jersey Date Terminated 2014-08-19
Cause 35:271 Patent Infringement Assigned To William H. Walls
Jury Demand Defendant Referred To Cathy L. Waldor
Parties CIPLA LTD.; G.D. SEARLE; G.D. SEARLE, LLC; JANSSEN PRODUCTS, L.P.; JANSSEN R&D IRELAND; JANSSEN R&D IRELAND; JANSSEN SCIENCES IRELAND UC; LUPIN LIMITED; LUPIN PHARMACEUTICALS INC.; MYLAN INC.; MYLAN PHARMACEUTICALS INC.; PHV THEODORE J. CHIACCHIO; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC.; THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS; TIBOTEC INC.; TIBOTEC PHARMACEUTICALS; UNITED STATES OF AMERICA
Patents 5,843,946; 6,248,775; 7,470,506; 7,700,645; RE42,889; RE43,596
Attorneys ANJAN MISHRA; CARISSA L. RODRIGUE; CHARLES MICHAEL LIZZA; COREY R. ANTHONY; DANIEL J. GIBBONS; ELINA SLAVIN; G.D. Searle; JAMES E. CECCHI; JOHN EDMUND FLAHERTY; JOHN G. NEW; JONATHAN M.H. SHORT; JOSEPH B. CRYSTAL; KIRBY WING-KAY LEE; MARK H. ANANIA; MAYRA VELEZ TARANTINO; MELISSA E. FLAX; MICHAEL CROSS; MICHAEL E. PATUNAS; RAVIN R. PATEL; SARAH ANN SULLIVAN; SYMONE J. REDWINE; WALTER WAYNE BROWN; WILLIAM C. BATON; ZHIQIANG LIU
Firms Attn: John E. Flaherty; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C.; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, PC; McCarter & English, LLP; McCarter and English, LLP; Office of the United States Atorney; Patterson Belknap Webb & Tyler LLP; Patunas Law LLC; Patunas Tarantino LLC; Saul Ewing Arnstein & Lehr LLP; Teva Pharmaceuticals USA, Inc.; U S Department of Justice; U.S. Department of Justice; United States Department of Justice, Civil Division, Commercial Litigation Branch
Link to Docket External link to docket
Small Molecule Drugs cited in JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

Date Filed Document No. Description Snippet Link To Document
2016-06-15 1073 of U.S. Patent No. 7,126,015 (the ‘015 Patent), and claim 4 of U.S. Patent No. 7,700,645 (the ‘645… the components protected by the ‘015 Patent or the ‘645 Patent. Id. Defendants Mylan and… the Patents and the end of any “associated pediatric exclusivity period” for the ‘645 Patent. Id. …would infringe claim 1 of the ‘015 Patent and/or claim 4 of the ‘645 Patent and enjoining Lupin from producing…Federal Rule of Civil Procedure 62.1. The case, a patent infringement action, is currently on appeal External link to document
2013-01-18 270 OPENING BRIEF FOR THE DISPUTED TERM IN U.S. PATENT RE43,596 (Attachments: # 1 Declaration of Irena Royzman…2010 19 August 2014 2:10-cv-05954 830 Patent Defendant District Court, D. External link to document
2013-01-18 271 Opening Brief of Defendants Regarding U.S. Patent No. RE43,596 E by LUPIN LIMITED, LUPIN PHARMACEUTICALS…2010 19 August 2014 2:10-cv-05954 830 Patent Defendant District Court, D. External link to document
2013-02-19 289 Responsive Markman Brief Regarding U.S. Patent No. RE43,596 E (Attachments: # 1 Supplemental Declaration… Responsive Markman Brief Regarding U.S. Patent No. RE43,596 E, # 2 Exhibit 7 to Declaration of Joseph… Responsive Markman Brief Regarding U.S. Patent No. RE43,596 E)(PATUNAS, MICHAEL) (Entered: 02/19/2013…2010 19 August 2014 2:10-cv-05954 830 Patent Defendant District Court, D. External link to document
2013-05-09 334 U.S. Patent No. 5,843, 946 (the “‘946 patent”) and U.S. Patent No. 7,700,645 (the “‘645 patent”). …asserted two more patents against Teva, U.S. Patent Nos. RE42,889 (the “‘889 patent”) and RE43,596 (…of the ‘946 patent, noting that claim 25 of the ‘889 patent and claim 7 of the ‘946 patent would both …on March 24, 2011, adding U.S. Patent No. 6,248,775 (the “‘775 patent”). (See D.E. 6, Civil Action…the ‘889 patent on June 13, 2012, and its complaint asserting infringement of the ‘596 patent August 24 External link to document
2013-06-18 373 U.S. Patent No. 5,843,946 (“the ‘946 patent”) and U.S. Patent No. 7,470,506 (“the ‘506 patent”). Plaintiffs…objections as to the ‘506 patent, and simply attempt to sweep them into the ’946 patent. Government Plaintiffs…its proposed amendment with respect to the ‘946 patent prior to August 7, 2012. Id. at 8-9. Instead, Janssen…for its proposed defenses to the ‘946 and ‘506 patents. Janssen Pls. Br. at 10-11. Finally, Janssen concludes…way eliminates all of Teva’s defenses to the ‘506 patent infringement claim). External link to document
2013-07-16 393 constructions and evidence for U.S Patent No. RE43,596 E (“‘596 patent”). The parties have sought construction…Regarding U.S. Patent No. RE43,596 E at 10 (emphasis in original). Local Patent Rule 4 controls… Intrinsic and Extrinsic Evidence for U.S. Patent RE43,596) at 2. On January 4, 2013, this proposed construction…No. RE43,596 E at 4. When Plaintiffs subsequently deposed Defendants’ expert, Dr. Laird, he agreed…596 patent: heterocycloalkyl and alkoxy.” Plaintiffs’ Opening Markman Brief Regarding U.S. Patent No. External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Fish and Richardson
Express Scripts
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.